3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, Non-Hodgkin
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Myelodysplastic Syndromes
3
Leukemia, Myeloid, Acute
3
Primary Myelofibrosis
2
Ovarian Neoplasms
2
Myeloproliferative Disorders
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Hodgkin Disease
2
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neoplasms
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Mesothelioma
1
Lymphoma, B-Cell
1
Leukemia, Prolymphocytic, B-Cell
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Biphenotypic, Acute
1
Kidney Neoplasms
1
Glioma
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Interventions
Nivolumab
28
pembrolizumab
24
cabozantinib
23
Ipilimumab
18
Specimen Handling
13
Magnetic Resonance Spectroscopy
13
Axitinib
12
lenvatinib
10
Radiosurgery
9
belzutifan
8
atezolizumab
6
CTLA-4 Antigen
6
Biopsy
6
cemiplimab
5
Radiotherapy
5
Bevacizumab
5
toripalimab
4
Everolimus
4
Blood Specimen Collection
4
avelumab
3
aldesleukin
3
X-Rays
3
Sunitinib
3
Standard of Care
3
Paclitaxel
3
zimberelimab
2
trastuzumab deruxtecan
2
tivozanib
2
spartalizumab
2
pazopanib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Carcinoma, Renal Cell
×
Blood Component Removal
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled